Cello Health (CLL)

Sector:

Health Care

Index:

FTSE AIM All-Share

123.00p
   
  • Change Today:
      1.00p
  • 52 Week High: 139.50p
  • 52 Week Low: 96.00p
  • Currency: UK Pounds
  • Shares Issued: 104.77m
  • Volume: 49,693
  • Market Cap: £128.87m
  • RiskGrade: 96

Deal with Barclays    Trade now with Barclays Stockbrokers

Monday broker round-up UPDATE

Date: Monday 31 Mar 2014

LONDON (ShareCast) - African Minerals: Credit Suisse cuts target price from 280p to 200p maintaining a neutral rating.

Anglo American: Credit Suisse reduces target price from 1900p to 1800p and retains an outperform rating.

ARM Holdings: Barclays takes target price from 1125p to 1200p and reiterates an overweight recommendation.

ASOS: Barclays increases target price from 6000p to 8000p, while its overweight rating remains unchanged.

Berendsen: UBS raises target price from 950p to 1100p keeping a neutral rating.

Cello Group: N+1 Singer lowers target price from 123p to 122p and retains a buy recommendation.

Clinigen Group: Numis takes target price from 620p to 650p upgrading to buy.

Daily Mail & General Trust: Westhouse Securities upgrades from neutral to add with a target price of 960p.

Darty: N+1 Singer ups target price to 140p and upgrades to buy.

easyJet: Numis raises target price from 1900p to 2100p upgrading to buy.

Ferrexpo: Barclays shifts target price from 170p to 175p and keeps a neutral rating.

Filtronic: Panmure Gordon reduces target price from 84p to 54p downgrading from buy to hold.

Glencore Xstrata: Credit Suisse cuts target price from 400p to 380p and retains an outperform rating.

Grainger: Jefferies ups target price from 239p to 260p and maintains a buy recommendation.

ITE Group: Westhouse Securities cuts target price from 215p to 206p and maintains a neutral rating.

Johnson Matthey: UBS raises target price from 3215p to 3275p and reiterates a neutral rating.

London Mining: Credit Suisse cuts target price from 170p to 140p leaving its outperform rating unaltered.

Majestic Wine: N+1 Singer cuts target price to 470p, while keeping its buy recommendation.

Morrison (Wm): Societe Generale cuts target price from 200p to 170p and stays with its sell recommendation.

Petards: Northland Capital reinitiates with a target price of 18p and a buy recommendation.

Phoenix Group: canaccord Genuity cuts target price from 865p to 800p, while leaving its buy recommendation unchanged.

Reckitt Benckiser: Deutsche Bank raises target price from 5100p to 6000p and retains its buy recommendation.

Regenersis: Panmure Gordon places both its target price and its buy recommendation under review.

Sage Group: Numis raises target price from 383p to 420p, while keeping its hold recommendation.

Sainsbury: Societe Generale cuts target price from 370p to 330p reiterating its hold recommendation.

Shanks Group: Investec downgrades from buy to add with a target price of 120p.

Sportech: Panmure Gordon ups target price from 153p to 184p maintaining a buy recommendation.

Travis Perkins: UBS moves target price from 2090p to 2100p and keeps a buy recommendation.

Vedanta Resources: Credit Suisse cuts target price from 1270p to 1150p, while staying with its outperform rating.

YouGov: Numis ups target price from 109p to 142p maintaining a buy recommendation.

Zambeef: Panmure Gordon places both its target price (prev.: 28p) and its sell recommendation under review.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Cello Health Market Data

Currency UK Pounds
Share Price 123.00p
Change Today 1.00p
% Change 0.82 %
52 Week High 139.50p
52 Week Low 96.00p
Volume 49,693
Shares Issued 104.77m
Market Cap £128.87m
RiskGrade 96

Cello Health Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
64.07% below the market average64.07% below the market average64.07% below the market average64.07% below the market average64.07% below the market average
65.71% above the sector average65.71% above the sector average65.71% above the sector average65.71% above the sector average65.71% above the sector average
Price Trend
0.35% above the market average0.35% above the market average0.35% above the market average0.35% above the market average0.35% above the market average
13.51% above the sector average13.51% above the sector average13.51% above the sector average13.51% above the sector average13.51% above the sector average
Income
15.54% above the market average15.54% above the market average15.54% above the market average15.54% above the market average15.54% above the market average
71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average
Growth
32.1% below the market average32.1% below the market average32.1% below the market average32.1% below the market average32.1% below the market average
33.33% below the sector average33.33% below the sector average33.33% below the sector average33.33% below the sector average33.33% below the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Cello Health Dividends

  Latest Previous
  Final Interim
Ex-Div 25-Apr-19 04-Oct-18
Paid 24-May-19 02-Nov-18
Amount 2.75p 1.10p

Trades for 13-Sep-2019

Time Volume / Share Price
17:08 5,000 @ 123.00p
12:46 663 @ 121.80p
11:03 12,500 @ 122.00p
10:57 12,500 @ 122.00p
09:42 2,500 @ 125.00p

Cello Health Key Personnel

CEO Mark Scott

Top of Page